Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
Opdivo with chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone in this patient population; approval based on
United States South Korea Ianm Waxman Bristol Myers Squibb Company Opdivo American Society Of Clinical Oncology
Source: finanznachrichten.de